Relay Therapeutics Expands Clinical Leadership Team with Addition of Tara O’Meara and Charles Ferté
Ms. O’Meara and Dr. Ferté bring extensive experience in drug development across oncology and genetic disease
May 03, 2021 06:00 ET | Source: Relay Therapeutics, Inc. Relay Therapeutics, Inc.
CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE)
Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, today announced the appointments of Tara O’Meara as senior vice president of clinical development operations, and Charles Ferté, M.D., Ph.D., as vice president, global medical lead for RLY-4008. Ms. O’Meara and Dr. Ferté bring decades of experience in the strategic oversight and execution of multiple drug development programs and will further strengthen the clinical team and Relay Therapeutics’ ability to
Relay Therapeutics Expands Clinical Leadership Team with Addition of Tara O’Meara and Charles Ferté - read this article along with other careers information, tips and advice on BioSpace
Resilience is an ambitious bet to improve cancer treatment
How two French entrepreneurs are methodically deconstructing and reconstructing cancer treatment to improve its efficiency
Meet Resilience, a new startup that wants to help cancer treatment institutes as well as cancer patients at every step of the treatment journey. It’s an ambitious project founded by two well-known French entrepreneurs. They want to leverage their tech skills for this new healthcare startup.
Behind the scenes, there are two co-CEOs Céline Lazorthes and Jonathan Benhamou. Nicolas Helleringer and Matthieu Pozza are the two remaining co-founders acting as CTO and CPO, respectively. Lazorthes previously co-founded Leetchi, the leading money pot company in France. She also started MangoPay, a marketplace payment solution, as a spinout company. Crédit Mutuel Arkéa acquired both companies.